(Q26824062)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22955856%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

16 December 2020

Human papillomavirus vaccination in low-resource countries: lack of evidence to support vaccinating sexually active women (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22955856%20AND%20SRC:MED&resulttype=core&format=json

Papillomavirus infections

12 February 2020

main subject

uterine cervix neoplasm

1 reference

16 December 2020

1 reference

PubMed publication ID

22955856

1 reference

16 December 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22955856%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

V Tsu

series ordinal

1

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22955856%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

M Murray

series ordinal

2

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22955856%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

1 reference

6 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22955856%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

12 February 2020

23 October 2012

1 reference

16 December 2020

10 references

13 March 2019

14 March 2019

23 March 2019

3 April 2019

20 June 2019

21 October 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22955856%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

29 May 2020

16 December 2020

107

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22955856%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

9

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22955856%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

1445-1450

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22955856%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

12 February 2020

copyright license

8 references

13 March 2019

14 March 2019

23 March 2019

3 April 2019

20 June 2019

21 October 2019

29 May 2020

on focus list of Wikimedia project

16 December 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

Time since first sexual intercourse and the risk of cervical cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

SOGC–GOC–SCC Joint Policy Statement. No. 255, March 2011. Cervical cancer prevention in low-resource settings.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

Human papillomavirus vaccines: current status and future prospects

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

Age-appropriate use of human papillomavirus vaccines in the U.S.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

Health and economic implications of HPV vaccination in the United States

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

Economic evaluation of human papillomavirus vaccination in the United Kingdom

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

Age considerations when vaccinating against HPV.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

Model for assessing human papillomavirus vaccination strategies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

HPV vaccination in women aged 24-45 years

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493757

HPV vaccination in women over 25 years of age: Asian Cervical Cancer Prevention Advisory Board recommendations.

31 May 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.404

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.404

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.404

Age-based programs for vaccination against HPV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.404

Variations in the age-specific curves of human papillomavirus prevalence in women worldwide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.404

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.404

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.404

Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.404

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.404

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.404

Why consider human papillomavirus vaccination in older women?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.404

Prophylactic human papillomavirus vaccines: will they do their job?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.404

Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.404

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.404

Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.404

Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses

21 January 2018

1 reference

12 December 2020

Human papillomavirus vaccine should be given before sexual debut for maximum benefit

1 reference

12 December 2020

At what age should we be vaccinating for human papillomavirus?

1 reference

12 December 2020

Prophylactic HPV vaccination for women over 18 years of age

1 reference

12 December 2020

Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines

1 reference

12 December 2020

Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model

1 reference

12 December 2020

Human papillomavirus vaccines. WHO position paper

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2012.404

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22955856%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

12 February 2020

0 references

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22955856%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

PubMed publication ID

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22955856%20AND%20SRC:MED&resulttype=core&format=json